We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-0.27%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.53B
AUM Growth
+$1.73M
Cap. Flow
-$160M
Cap. Flow %
-10.45%
Top 10 Hldgs %
69.53%
Holding
250
New
32
Increased
47
Reduced
70
Closed
82

Top Buys

Rank Stock Value
1
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$13.5M
2
ARAV
Aravive, Inc. Common Stock
ARAV
+$11.9M
3
ESPR
Esperion Therapeutics
ESPR
+$4.02M
4
AIXC
AIxCrypto Holdings Inc
AIXC
+$2.59M
5
HURA
TuHURA Biosciences
HURA
+$2.3M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$59.2M
2
UTHR icon
United Therapeutics
UTHR
+$6.78M
3
TSRO
TESARO, Inc.
TSRO
+$5.95M
4
KITE
Kite Pharma, Inc.
KITE
+$4.37M
5
SPNC
Spectranetics Corp
SPNC
+$3.48M

Sector Composition

Rank Sector Weight
1 Healthcare 7.34%
2 Technology 0.16%
3 Materials 0.11%
4 Consumer Staples 0.04%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRIS icon
176
Curis
CRIS
$9.67M
– –
-24
Closed -$91K
CRIS icon
177
PUT
Curis
CRIS
$9.67M
– –
0
– -$91K
CSBR icon
178
Champions Oncology
CSBR
$75.2M
– –
-71,700
Closed -$184K
CTSO icon
179
Cytosorbents Corp
CTSO
$22.6M
– –
-172,100
Closed -$740K
DBVT
180
DBV Technologies
DBVT
$794M
– –
-3,750
Closed -$1.61M
DRRX
181
CALL
DELISTED
DURECT Corp
DRRX
– –
-486
Closed -$758K
DRRX
182
DELISTED
DURECT Corp
DRRX
– –
-42,500
Closed -$663K
DVAX
183
CALL
DELISTED
Dynavax Technologies
DVAX
– –
-12,493
Closed -$12.1M
DVAX
184
PUT
DELISTED
Dynavax Technologies
DVAX
– –
-219
Closed -$211K
EDIT icon
185
CALL
Editas Medicine
EDIT
$388M
– –
-881
Closed -$291K
EDIT icon
186
Editas Medicine
EDIT
$388M
– –
-85,000
Closed -$1.43M
CHRN
187
PUT
ChronoScale Holdings
CHRN
$2.91B
– –
-1
Closed -$30K
IMMP
188
Immutep
IMMP
$57M
– –
-962,835
Closed -$1.99M
INDP icon
189
Indaptus Therapeutics
INDP
$252M
– –
-41
Closed -$528K
IOVA icon
190
Iovance Biotherapeutics
IOVA
$2.02B
– –
-71,251
Closed -$524K
IOVA icon
191
PUT
Iovance Biotherapeutics
IOVA
$2.02B
– –
-195
Closed -$140K
LXRX icon
192
PUT
Lexicon Pharmaceuticals
LXRX
$1.02B
– –
-457
Closed -$752K
NSPR icon
193
InspireMD
NSPR
$32.3M
– –
-1
Closed -$15K
NTLA icon
194
CALL
Intellia Therapeutics
NTLA
$1.48B
– –
-452
Closed -$723K
PALI icon
195
PUT
Palisade Bio
PALI
$334M
– –
0
– -$157K
PCRX icon
196
CALL
Pacira BioSciences
PCRX
$1.04B
– –
-679
Closed -$3.24M
PCRX icon
197
Pacira BioSciences
PCRX
$1.04B
– –
-4,390
Closed -$209K
PCRX icon
198
PUT
Pacira BioSciences
PCRX
$1.04B
– –
-678
Closed -$3.23M
PSTV icon
199
Plus Therapeutics
PSTV
$24.6M
– –
-9
Closed -$1.79M
PTN
200
Palatin Technologies
PTN
$13.9M
– –
-443
Closed -$238K
6 7
8
9 10

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2017 Portfolio in Review

As of Q3 2017, Sabby Management held 250 positions worth $1.53B, up 0.11% from $1.53B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Sabby Management withdrew a net $160M in Q3 2017, closing 82 positions and reducing 70 holdings. Its most notable exit was United Therapeutics, an estimated $6.78M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 7.3% of assets, down from 13% a quarter earlier, followed by Technology and Materials.

Against the trend, Sabby Management opened a new position in Sio Gene Therapies Inc. Common Stock worth $4.42M.

  • Sabby Management's largest Q3 2017 buy was Sio Gene Therapies Inc. Common Stock: 80,320 shares worth $4.42M.
  • Sabby Management added most to TuHURA Biosciences in Q3 2017, an estimated $2.3M increase.
  • Sabby Management's biggest Q3 2017 reduction was Bristol-Myers Squibb, cutting an estimated $59.2M.
  • Sabby Management fully exited United Therapeutics in Q3 2017, selling an estimated $6.78M.
  • Sabby Management's ten largest holdings make up 70% of its $1.53B portfolio in Q3 2017.
  • Sabby Management opened 32 new positions and closed 82 in Q3 2017.
  • Sabby Management's portfolio value rose 0.11% quarter-over-quarter to $1.53B.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.